Trial Profile
Drug Use Investigation on Combination Therapy With Yervoy and Opdivo (Unresectable or Metastatic Renal Cell Carcinoma)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 09 Feb 2022 Status changed from recruiting to completed.
- 23 Oct 2018 Status changed from not yet recruiting to recruiting.
- 18 Sep 2018 New trial record